Abstract
Cancer cachexia is a complex catabolic state in patients with a malignancy, associated with increased morbidity and mortality. This syndrome is characterized by a redistribution of the body’s protein content and a subsequent muscle wasting. The aetiology of this syndrome seems multifactorial, but remains unclear. It is suggested that this catabolic state occurs in response to the alterations in immune interactions between tumor and host. The amino acid arginine and its derivate nitric oxide (NO) play various roles in anti-tumor immune response and the body’s homeostasis. Glutamine is the precursor for arginine de novo synthesis and the most abundant amino acid in the body, mainly stored in skeletal muscle. Tumors develop a protection mechanism against the specific anti-tumor attack of the immune system by recruiting myeloid derived suppressor cells (MDSC). The MDSC deplete arginine levels and disturb NO production. We here hypothesize that the perturbation of the arginine/NO metabolism plays a significant role in the aetiology of cancer cachexia. Arginine/ NO metabolism is disturbed in patients with cancer. The body will try to correct this perturbation by mobilizing arginine and glutamine from muscles. The decreased arginine levels and the disturbed NO production activate several cascades, which in turn inhibit protein synthesis and promote proteolysis, leading to cachexia. Cachexia remains one of the most frequent and damaging opportunistic syndromes in cancer patients. In this review we will elaborate on a new hypothesised concept and the underlying mechanisms of this syndrome. New studies are essential to ground this hypothesis and to develop interventions to break through the pathological mechanisms underlying cachexia.
Keywords: Arginase, arginine, cancer cachexia, glutamine, immune system, iNOS, MDSC, nitric oxide, protein synthesis, proteolysis
Current Medicinal Chemistry
Title:The Role of a Disturbed Arginine/NO Metabolism in the Onset of Cancer Cachexia: A Working Hypothesis
Volume: 19 Issue: 31
Author(s): N. Buijs, J. Luttikhold, A.P.J. Houdijk and P.A.M. van Leeuwen
Affiliation:
Keywords: Arginase, arginine, cancer cachexia, glutamine, immune system, iNOS, MDSC, nitric oxide, protein synthesis, proteolysis
Abstract: Cancer cachexia is a complex catabolic state in patients with a malignancy, associated with increased morbidity and mortality. This syndrome is characterized by a redistribution of the body’s protein content and a subsequent muscle wasting. The aetiology of this syndrome seems multifactorial, but remains unclear. It is suggested that this catabolic state occurs in response to the alterations in immune interactions between tumor and host. The amino acid arginine and its derivate nitric oxide (NO) play various roles in anti-tumor immune response and the body’s homeostasis. Glutamine is the precursor for arginine de novo synthesis and the most abundant amino acid in the body, mainly stored in skeletal muscle. Tumors develop a protection mechanism against the specific anti-tumor attack of the immune system by recruiting myeloid derived suppressor cells (MDSC). The MDSC deplete arginine levels and disturb NO production. We here hypothesize that the perturbation of the arginine/NO metabolism plays a significant role in the aetiology of cancer cachexia. Arginine/ NO metabolism is disturbed in patients with cancer. The body will try to correct this perturbation by mobilizing arginine and glutamine from muscles. The decreased arginine levels and the disturbed NO production activate several cascades, which in turn inhibit protein synthesis and promote proteolysis, leading to cachexia. Cachexia remains one of the most frequent and damaging opportunistic syndromes in cancer patients. In this review we will elaborate on a new hypothesised concept and the underlying mechanisms of this syndrome. New studies are essential to ground this hypothesis and to develop interventions to break through the pathological mechanisms underlying cachexia.
Export Options
About this article
Cite this article as:
Buijs N., Luttikhold J., Houdijk A.P.J. and van Leeuwen P.A.M., The Role of a Disturbed Arginine/NO Metabolism in the Onset of Cancer Cachexia: A Working Hypothesis, Current Medicinal Chemistry 2012; 19 (31) . https://dx.doi.org/10.2174/092986712803833290
DOI https://dx.doi.org/10.2174/092986712803833290 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Current Pharmaceutical Design Engineered Liposomes for Drug Delivery and Biomedical Imaging
Recent Patents on Nanomedicine Circulating Tumor Stem Cells as Biomarkers for Cancer Progression
Recent Patents on Biomarkers Differentiated Thyroid Carcinoma and Intestinal Polyposis Syndromes
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Patents on Anti-Cancer Potential of Helenalin
Recent Patents on Anti-Cancer Drug Discovery Role of TGF- β in the Tumor Stroma
Current Cancer Drug Targets Nanoprobes for Medical Diagnosis: Current Status of Nanotechnology in Molecular Imaging
Current Nanoscience Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Ion Exchange Resins Transforming Drug Delivery Systems
Current Drug Delivery Meet Our Editorial Board Member
The Natural Products Journal Role of Genetics and Epigenetics in Mucosal, Uveal, and Cutaneous Melanomagenesis
Anti-Cancer Agents in Medicinal Chemistry Cryptogenic Liver Diseases: Sailing by Sight from HIV Co-Infection with Hepatitis Viruses to HIV Mono-Infection Through the Pillars of Hercules
Current HIV Research Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Advances in Oncolytic Virus Therapy for Glioma
Recent Patents on CNS Drug Discovery (Discontinued) Natural Products Triggering Biological Targets- A Review of the Anti-Inflammatory Phytochemicals Targeting the Arachidonic Acid Pathway in Allergy Asthma and Rheumatoid Arthritis
Current Drug Targets How to Measure Pharmacokinetics in Critically Ill Patients?
Current Pharmaceutical Biotechnology mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy
Current Cancer Drug Targets The Effects of 5-Aza-2`-Deoxycytidine on DLC-1 Gene Expression, Methylation Level and Expression of Downstream Signaling Molecules Cdc42 in Multiple Myeloma
Current Signal Transduction Therapy Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging